Clinical Trials Browser

Simpson-Golabi-Behmel syndrome × Bevacizumab × 30 days × Clear all

NCT06427941 2026-03-18

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular